JP2020514316A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020514316A5 JP2020514316A5 JP2019540532A JP2019540532A JP2020514316A5 JP 2020514316 A5 JP2020514316 A5 JP 2020514316A5 JP 2019540532 A JP2019540532 A JP 2019540532A JP 2019540532 A JP2019540532 A JP 2019540532A JP 2020514316 A5 JP2020514316 A5 JP 2020514316A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical composition
- diastereomer
- enantiomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 45
- 150000003839 salts Chemical group 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 208000011580 syndromic disease Diseases 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 150000003573 thiols Chemical class 0.000 claims description 16
- 208000036142 Viral infection Diseases 0.000 claims description 12
- 125000001153 fluoro group Chemical group F* 0.000 claims description 12
- 230000009385 viral infection Effects 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 8
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 206010060862 Prostate cancer Diseases 0.000 claims description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 8
- 125000004429 atom Chemical group 0.000 claims description 8
- 208000029742 colonic neoplasm Diseases 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- 201000001441 melanoma Diseases 0.000 claims description 8
- 150000002431 hydrogen Chemical group 0.000 claims description 7
- DNISYQIZVIFCRA-UHFFFAOYSA-N 4-(1-aminoethyl)-2,6-ditert-butylphenol Chemical compound CC(N)C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 DNISYQIZVIFCRA-UHFFFAOYSA-N 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 208000002672 hepatitis B Diseases 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000000375 suspending agent Substances 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022129286A JP2022163188A (ja) | 2017-01-27 | 2022-08-15 | Ｓｔｉｎｇアゴニストとしての環状ジヌクレオチド |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762451285P | 2017-01-27 | 2017-01-27 | |
| US62/451,285 | 2017-01-27 | ||
| US201762454131P | 2017-02-03 | 2017-02-03 | |
| US62/454,131 | 2017-02-03 | ||
| PCT/IB2018/050497 WO2018138684A1 (en) | 2017-01-27 | 2018-01-26 | Cyclic dinucleotides as sting agonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022129286A Division JP2022163188A (ja) | 2017-01-27 | 2022-08-15 | Ｓｔｉｎｇアゴニストとしての環状ジヌクレオチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020514316A JP2020514316A (ja) | 2020-05-21 |
| JP2020514316A5 true JP2020514316A5 (enExample) | 2021-03-04 |
| JP7213188B2 JP7213188B2 (ja) | 2023-01-26 |
Family
ID=61187609
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019540532A Active JP7213188B2 (ja) | 2017-01-27 | 2018-01-26 | Ｓｔｉｎｇアゴニストとしての環状ジヌクレオチド |
| JP2022129286A Pending JP2022163188A (ja) | 2017-01-27 | 2022-08-15 | Ｓｔｉｎｇアゴニストとしての環状ジヌクレオチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022129286A Pending JP2022163188A (ja) | 2017-01-27 | 2022-08-15 | Ｓｔｉｎｇアゴニストとしての環状ジヌクレオチド |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11021511B2 (enExample) |
| EP (1) | EP3573717B1 (enExample) |
| JP (2) | JP7213188B2 (enExample) |
| CN (1) | CN110234404A (enExample) |
| AU (1) | AU2018212787B2 (enExample) |
| ES (1) | ES2891326T3 (enExample) |
| WO (1) | WO2018138684A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102530488B1 (ko) | 2016-03-18 | 2023-05-08 | 이뮨 센서, 엘엘씨 | 사이클릭 디-뉴클레오티드 화합물 및 사용 방법 |
| JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
| CN111263767B (zh) | 2017-08-30 | 2023-07-18 | 北京轩义医药科技有限公司 | 作为干扰素基因调节剂的刺激剂的环状二核苷酸 |
| US11542293B2 (en) | 2017-11-10 | 2023-01-03 | Takeda Pharmaceutical Company Limited | Sting modulator compounds, and methods of making and using |
| US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
| WO2020092127A1 (en) | 2018-10-29 | 2020-05-07 | Venenum Biodesign, LLC | Novel sting agonists |
| CN113382772B (zh) * | 2018-11-19 | 2025-01-07 | 艾福姆德尤股份有限公司 | 用于治疗与sting活性有关的疾病的化合物和组合物 |
| WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
| CA3137119A1 (en) * | 2019-05-09 | 2020-11-12 | Aligos Therapeutics, Inc. | Modified cyclic dinucleoside compounds as sting modulators |
| CN114340680A (zh) | 2019-07-05 | 2022-04-12 | 坦博公司 | 反式环辛烯生物正交剂及在癌症和免疫疗法中的用途 |
| TW202200136A (zh) | 2020-04-10 | 2022-01-01 | 日商小野藥品工業股份有限公司 | 癌治療方法 |
| WO2021252904A1 (en) * | 2020-06-11 | 2021-12-16 | Massachusetts Institute Of Technology | Ribonucleoprotein approach to boost the sting signaling for cancer immunotherapy |
| CN116056765A (zh) | 2020-08-07 | 2023-05-02 | 坦伯公司 | 反式环辛烯生物正交剂及在癌症和免疫疗法中的用途 |
| JP7397996B2 (ja) | 2020-11-09 | 2023-12-13 | 武田薬品工業株式会社 | 抗体薬物コンジュゲート |
| PE20240931A1 (es) | 2021-08-10 | 2024-04-30 | Ifm Due Inc | Compuestos y composiciones para tratar condiciones asociadas con actividad de sting |
| CN120757600B (zh) * | 2025-09-10 | 2025-11-11 | 天津法尔玛制药有限公司 | 环二核苷酸2′,3′-cG4′-MeAMP、制备方法及其在制备先天免疫激活剂中的应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020142000A1 (en) | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| AU2002234755A1 (en) | 2001-02-26 | 2002-09-12 | Pharma Pacific Pty Ltd | Interferon-alpha induced gene |
| JPWO2005005450A1 (ja) * | 2003-07-15 | 2006-08-24 | 三井化学株式会社 | 環状ビスジヌクレオチドの合成方法 |
| AU2006265108C1 (en) | 2005-07-01 | 2013-01-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
| WO2010027827A2 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Targeted costimulatory polypeptides and methods of use to treat cancer |
| KR20190069615A (ko) | 2008-12-09 | 2019-06-19 | 제넨테크, 인크. | 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도 |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| TR201820873T4 (tr) | 2011-08-01 | 2019-01-21 | Hoffmann La Roche | Pd-1 ekseni bağlayıcı antagonistler ve mek inhibitörlerinin kullanıldığı kanser tedavisine yönelik yöntemler. |
| AP2015008746A0 (en) * | 2013-04-29 | 2015-09-30 | Univ Bonn | Compositions and methods for altering second messenger signaling |
| KR20160009039A (ko) | 2013-05-18 | 2016-01-25 | 아두로 바이오테크, 인코포레이티드 | “인터페론 유전자의 자극기”-의존성 신호전달을 활성화하기 위한 조성물 및 방법 |
| US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
| JP6400082B2 (ja) | 2013-05-18 | 2018-10-03 | アデュロ バイオテック，インコーポレイテッド | 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を抑制するための組成物および方法 |
| US20160287623A1 (en) | 2013-11-19 | 2016-10-06 | The University Of Chicago | Use of sting agonist as cancer treatment |
| JP6462006B2 (ja) | 2014-06-04 | 2019-01-30 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｓｔｉｎｇのモジュレーターとしての環式ジヌクレオチド |
| US20180344758A1 (en) * | 2014-12-17 | 2018-12-06 | Lipogen Llc | Method of Treating Cancer with cGAMP or cGAsMP |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| BR112018002757A8 (pt) | 2015-08-13 | 2023-04-11 | Merck Sharp & Dohme | Composto, composição farmacêutica, e, métodos para induzir uma resposta imune, para induzir uma produção de interferon tipo i e para tratamento de um distúrbio |
| BR112018008339A2 (pt) | 2015-10-28 | 2018-10-30 | Aduro Biotech Inc | composições e métodos para ativar estimulador de sinalização dependente do gene de interferon |
| PE20181297A1 (es) | 2015-12-03 | 2018-08-07 | Glaxosmithkline Ip Dev Ltd | Dinucleotidos de purino ciclico como moduladores de sting |
| KR102530488B1 (ko) | 2016-03-18 | 2023-05-08 | 이뮨 센서, 엘엘씨 | 사이클릭 디-뉴클레오티드 화합물 및 사용 방법 |
| EP3448393A1 (en) | 2016-04-25 | 2019-03-06 | Invivogen | Novel complexes of immunostimulatory compounds, and uses thereof |
| US11098077B2 (en) * | 2016-07-05 | 2021-08-24 | Chinook Therapeutics, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| JOP20170188A1 (ar) * | 2016-11-25 | 2019-01-30 | Janssen Biotech Inc | ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting) |
| JP2020511420A (ja) * | 2016-12-20 | 2020-04-16 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | がんの処置のためのｐｄ−１アンタゴニストと環状ジヌクレオチドｓｔｉｎｇアゴニストとの組み合わせ |
| EP3558324A4 (en) * | 2016-12-20 | 2020-08-05 | Merck Sharp & Dohme Corp. | CYCLIC STING DINUCLEOTID AGONISTS FOR CANCER TREATMENT |
-
2018
- 2018-01-26 ES ES18703857T patent/ES2891326T3/es active Active
- 2018-01-26 AU AU2018212787A patent/AU2018212787B2/en not_active Expired - Fee Related
- 2018-01-26 EP EP18703857.5A patent/EP3573717B1/en active Active
- 2018-01-26 JP JP2019540532A patent/JP7213188B2/ja active Active
- 2018-01-26 WO PCT/IB2018/050497 patent/WO2018138684A1/en not_active Ceased
- 2018-01-26 US US16/478,864 patent/US11021511B2/en not_active Expired - Fee Related
- 2018-01-26 CN CN201880009027.3A patent/CN110234404A/zh active Pending
-
2022
- 2022-08-15 JP JP2022129286A patent/JP2022163188A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020514316A5 (enExample) | ||
| JP2020500862A5 (enExample) | ||
| JP2020505405A5 (enExample) | ||
| CN111989332A (zh) | 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用 | |
| JP2020507589A5 (enExample) | ||
| JP2013545730A5 (enExample) | ||
| JP2012525393A5 (enExample) | ||
| JP2012505836A5 (enExample) | ||
| JP2017531619A5 (enExample) | ||
| JP2016534063A5 (enExample) | ||
| JP2019537570A5 (enExample) | ||
| JP2020097577A5 (enExample) | ||
| JP2020512337A5 (enExample) | ||
| JP2005506352A5 (enExample) | ||
| JP2011057693A5 (enExample) | ||
| JP2006523216A5 (enExample) | ||
| JP2013010792A5 (enExample) | ||
| JP2009535352A5 (enExample) | ||
| JP2014505008A5 (enExample) | ||
| JP2019526596A5 (enExample) | ||
| CA2682494A1 (en) | Hexahydro-1h-4,7-methanoisoindole-1,3-dione compounds for treating psychiatric disorders | |
| JP2015096544A5 (enExample) | ||
| JP2017526677A5 (enExample) | ||
| JP2019520344A5 (enExample) | ||
| JP2018534288A5 (enExample) |